Robert Shenkar1, Changbin Shi1, Cecilia Austin1, Thomas Moore1, Rhonda Lightle1, Ying Cao1, Lingjiao Zhang1, Meijing Wu1, Hussein A Zeineddine1, Romuald Girard1, David A McDonald1, Autumn Rorrer1, Carol Gallione1, Peter Pytel1, James K Liao1, Douglas A Marchuk1, Issam A Awad2. 1. From the Section of Neurosurgery (R.S., C.S., C.A., T.M., R.L., Y.C., L.Z., M.W., H.A.Z., R.G., I.A.A.), Department of Pathology (P.P.), Section of Cardiology (J.K.L.), Biological Sciences Division, University of Chicago, IL; and the Molecular Genetics and Microbiology Department, Duke University Medical Center, Durham, NC (D.A. McDonald, A.R., C.G., D.A. Marchuk). 2. From the Section of Neurosurgery (R.S., C.S., C.A., T.M., R.L., Y.C., L.Z., M.W., H.A.Z., R.G., I.A.A.), Department of Pathology (P.P.), Section of Cardiology (J.K.L.), Biological Sciences Division, University of Chicago, IL; and the Molecular Genetics and Microbiology Department, Duke University Medical Center, Durham, NC (D.A. McDonald, A.R., C.G., D.A. Marchuk). iawad@uchicago.edu.
Abstract
BACKGROUND AND PURPOSE: We sought to compare the effect of chronic treatment with commonly tolerated doses of Fasudil, a specific RhoA kinase (ROCK) inhibitor, and simvastatin (with pleiotropic effects including ROCK inhibition) on cerebral cavernous malformation (CCM) genesis and maturation in 2 models that recapitulate the human disease. METHODS: Two heterozygous murine models, Ccm1+/-Msh2-/- and Ccm2+/-Trp53-/-, were treated from weaning to 4 to 5 months of age with Fasudil (100 mg/kg per day), simvastatin (40 mg/kg per day) or with placebo. Mouse brains were blindly assessed for CCM lesion burden, nonheme iron deposition (as a quantitative measure of chronic lesional hemorrhage), and ROCK activity. RESULTS: Fasudil, but not simvastatin, significantly decreased mature CCM lesion burden in Ccm1+/-Msh2-/- mice, and in meta-analysis of both models combined, when compared with mice receiving placebo. Fasudil and simvastatin both significantly decreased the integrated iron density per mature lesion area in Ccm1+/-Msh2-/- mice, and in both models combined, compared with mice given placebo. ROCK activity in mature lesions of Ccm1+/-Msh2-/- mice was similar with both treatments. Fasudil, but not simvastatin, improved survival in Ccm1+/-Msh2-/- mice. Fasudil and simvastatin treatment did not affect survival or lesion development significantly in Ccm2+/-Trp53-/- mice alone, and Fasudil benefit seemed limited to males. CONCLUSIONS: ROCK inhibitor Fasudil was more efficacious than simvastatin in improving survival and blunting the development of mature CCM lesions. Both drugs significantly decreased chronic hemorrhage in CCM lesions. These findings justify the development of ROCK inhibitors and the clinical testing of commonly used statin agents in CCM.
BACKGROUND AND PURPOSE: We sought to compare the effect of chronic treatment with commonly tolerated doses of Fasudil, a specific RhoA kinase (ROCK) inhibitor, and simvastatin (with pleiotropic effects including ROCK inhibition) on cerebral cavernous malformation (CCM) genesis and maturation in 2 models that recapitulate the human disease. METHODS: Two heterozygous murine models, Ccm1+/-Msh2-/- and Ccm2+/-Trp53-/-, were treated from weaning to 4 to 5 months of age with Fasudil (100 mg/kg per day), simvastatin (40 mg/kg per day) or with placebo. Mouse brains were blindly assessed for CCM lesion burden, nonheme iron deposition (as a quantitative measure of chronic lesional hemorrhage), and ROCK activity. RESULTS:Fasudil, but not simvastatin, significantly decreased mature CCM lesion burden in Ccm1+/-Msh2-/- mice, and in meta-analysis of both models combined, when compared with mice receiving placebo. Fasudil and simvastatin both significantly decreased the integrated iron density per mature lesion area in Ccm1+/-Msh2-/- mice, and in both models combined, compared with mice given placebo. ROCK activity in mature lesions of Ccm1+/-Msh2-/- mice was similar with both treatments. Fasudil, but not simvastatin, improved survival in Ccm1+/-Msh2-/- mice. Fasudil and simvastatin treatment did not affect survival or lesion development significantly in Ccm2+/-Trp53-/- mice alone, and Fasudil benefit seemed limited to males. CONCLUSIONS:ROCK inhibitor Fasudil was more efficacious than simvastatin in improving survival and blunting the development of mature CCM lesions. Both drugs significantly decreased chronic hemorrhage in CCM lesions. These findings justify the development of ROCK inhibitors and the clinical testing of commonly used statin agents in CCM.
Authors: David A McDonald; Robert Shenkar; Changbin Shi; Rebecca A Stockton; Amy L Akers; Melanie H Kucherlapati; Raju Kucherlapati; James Brainer; Mark H Ginsberg; Issam A Awad; Douglas A Marchuk Journal: Hum Mol Genet Date: 2010-10-11 Impact factor: 6.150
Authors: Romuald Girard; Hussein A Zeineddine; Courtney Orsbon; Huan Tan; Thomas Moore; Nick Hobson; Robert Shenkar; Rhonda Lightle; Changbin Shi; Maged D Fam; Ying Cao; Le Shen; April I Neander; Autumn Rorrer; Carol Gallione; Alan T Tang; Mark L Kahn; Douglas A Marchuk; Zhe-Xi Luo; Issam A Awad Journal: J Neurosci Methods Date: 2016-06-23 Impact factor: 2.390
Authors: Kevin J Whitehead; Aubrey C Chan; Sutip Navankasattusas; Wonshill Koh; Nyall R London; Jing Ling; Anne H Mayo; Stavros G Drakos; Christopher A Jones; Weiquan Zhu; Douglas A Marchuk; George E Davis; Dean Y Li Journal: Nat Med Date: 2009-01-18 Impact factor: 53.440
Authors: Robert Shenkar; Changbin Shi; Douglas A Marchuk; Issam A Awad; Tania Rebeiz; Rebecca A Stockton; David A McDonald; Abdul Ghani Mikati; Lingjiao Zhang; Cecilia Austin; Amy L Akers; Carol J Gallione; Autumn Rorrer; Murat Gunel; Wang Min; Jorge Marcondes De Souza; Connie Lee Journal: Genet Med Date: 2014-08-14 Impact factor: 8.822
Authors: Sayoko Nishimura; Ketu Mishra-Gorur; JinSeok Park; Yulia V Surovtseva; Said M Sebti; Andre Levchenko; Angeliki Louvi; Murat Gunel Journal: Proc Natl Acad Sci U S A Date: 2017-05-12 Impact factor: 11.205
Authors: Lisa McKerracher; Robert Shenkar; Matthew Abbinanti; Ying Cao; Amy Peiper; James K Liao; Rhonda Lightle; Thomas Moore; Nicholas Hobson; Carol Gallione; Joerg Ruschel; Janne Koskimäki; Romuald Girard; Kenneth Rosen; Douglas A Marchuk; Issam A Awad Journal: Transl Stroke Res Date: 2019-08-24 Impact factor: 6.829
Authors: Alan T Tang; Katie R Sullivan; Courtney C Hong; Lauren M Goddard; Aparna Mahadevan; Aileen Ren; Heidy Pardo; Amy Peiper; Erin Griffin; Ceylan Tanes; Lisa M Mattei; Jisheng Yang; Li Li; Patricia Mericko-Ishizuka; Le Shen; Nicholas Hobson; Romuald Girard; Rhonda Lightle; Thomas Moore; Robert Shenkar; Sean P Polster; Claudia J Roedel; Ning Li; Qin Zhu; Kevin J Whitehead; Xiangjian Zheng; Amy Akers; Leslie Morrison; Helen Kim; Kyle Bittinger; Christopher J Lengner; Markus Schwaninger; Anna Velcich; Leonard Augenlicht; Salim Abdelilah-Seyfried; Wang Min; Douglas A Marchuk; Issam A Awad; Mark L Kahn Journal: Sci Transl Med Date: 2019-11-27 Impact factor: 17.956
Authors: Richard F Keep; Anuska V Andjelkovic; Jianming Xiang; Svetlana M Stamatovic; David A Antonetti; Ya Hua; Guohua Xi Journal: J Cereb Blood Flow Metab Date: 2018-05-08 Impact factor: 6.200
Authors: Marc C Mabray; Arvind Caprihan; Jeffrey Nelson; Charles E McCulloch; Atif Zafar; Helen Kim; Blaine L Hart; Leslie Morrison Journal: Transl Stroke Res Date: 2019-10-23 Impact factor: 6.829
Authors: Sean P Polster; Ying Cao; Timothy Carroll; Kelly Flemming; Romuald Girard; Daniel Hanley; Nicholas Hobson; Helen Kim; James Koenig; Janne Koskimäki; Karen Lane; Jennifer J Majersik; Nichol McBee; Leslie Morrison; Robert Shenkar; Agnieszka Stadnik; Richard E Thompson; Joseph Zabramski; Hussein A Zeineddine; Issam A Awad Journal: Neurosurgery Date: 2019-04-01 Impact factor: 4.654